• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型 N2-取代的吡唑并[3,4-d]嘧啶腺苷 A3 受体拮抗剂:抑制 A3 介导的人神经胶质瘤细胞增殖。

Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.

机构信息

Dipartimento di Scienze Farmaceutiche, Università di Pisa, Pisa, Italy.

出版信息

J Med Chem. 2010 May 27;53(10):3954-63. doi: 10.1021/jm901785w.

DOI:10.1021/jm901785w
PMID:20408530
Abstract

Adenosine induces glioma cell proliferation by means of an antiapoptotic effect, which is blocked by cotreatment with selective A(3) AR antagonists. In this study, a novel series of N(2)-substituted pyrazolo[3,4-d]pyrimidines 2a-u was developed as highly potent and selective A(3) AR antagonists. The most performing compounds were derivatives 2a (R(1) = CH(3) and R(2) = COC(6)H(5); K(i) 334, 728, and 0.60 nM at the human A(1), A(2A), and A(3) ARs, respectively) and 2b (R(1) = CH(3) and R(2) = COC(6)H(4)-4-OCH(3); K(i) 1037, 3179, and 0.18 nM at the human A(1), A(2A), and A(3) ARs, respectively), which counteracted the effect of the A(3) AR agonists Cl-IB-MECA and IB-MECA on human glioma U87MG cell proliferation. This effect was concentration-dependent, with IC(50) values comparable to A(3) AR binding affinity values of 2a and 2b, thereby suggesting that their effects were receptor-mediated. Furthermore, the antiproliferative activity of the new compounds was demonstrated to be mediated by the block of A(3) AR agonist activation of intracellular kinases ERK 1/2.

摘要

腺嘌呤通过抗细胞凋亡作用诱导神经胶质瘤细胞增殖,这种作用可被选择性 A(3)AR 拮抗剂的共同处理所阻断。在这项研究中,开发了一系列新型的 N(2)-取代的吡唑并[3,4-d]嘧啶 2a-u 作为高活性和选择性的 A(3)AR 拮抗剂。表现最出色的化合物是衍生物 2a(R(1) = CH(3) 和 R(2) = COC(6)H(5);在人 A(1)、A(2A)和 A(3)AR 上的 K(i)分别为 334、728 和 0.60 nM)和 2b(R(1) = CH(3) 和 R(2) = COC(6)H(4)-4-OCH(3);在人 A(1)、A(2A)和 A(3)AR 上的 K(i)分别为 1037、3179 和 0.18 nM),它们能拮抗 A(3)AR 激动剂 Cl-IB-MECA 和 IB-MECA 对人神经胶质瘤 U87MG 细胞增殖的作用。这种作用呈浓度依赖性,IC(50)值与 2a 和 2b 的 A(3)AR 结合亲和力值相当,表明其作用是受体介导的。此外,新化合物的抗增殖活性被证明是通过阻断 A(3)AR 激动剂激活细胞内激酶 ERK 1/2 介导的。

相似文献

1
Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.新型 N2-取代的吡唑并[3,4-d]嘧啶腺苷 A3 受体拮抗剂:抑制 A3 介导的人神经胶质瘤细胞增殖。
J Med Chem. 2010 May 27;53(10):3954-63. doi: 10.1021/jm901785w.
2
The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.2-呋喃环取代 2-(对位取代)芳基在一系列新型吡唑并三唑嘧啶中的意义作为有效的和高度选择性的 hA(3) 腺苷受体拮抗剂:对结构-亲和力关系和受体-拮抗剂识别的新见解。
J Med Chem. 2010 Apr 22;53(8):3361-75. doi: 10.1021/jm100049f.
3
Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.新型 A2A 和 A3 腺苷受体拮抗剂 C9 和 C2 取代的吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶的设计、合成及生物学评价
J Med Chem. 2003 Mar 27;46(7):1229-41. doi: 10.1021/jm021023m.
4
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.吡唑并[4,3-e]-1,2,4-三唑并[1,5-c]嘧啶衍生物作为腺苷受体拮抗剂。N5取代基对人A3和A2B腺苷受体亚型亲和力的影响:分子模拟研究。
J Med Chem. 2003 Sep 25;46(20):4287-96. doi: 10.1021/jm030852k.
5
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.2-苯基吡唑并[4,3-d]嘧啶-7-酮作为一种新型骨架用于获得强效且选择性的人A3腺苷受体拮抗剂:受体-拮抗剂识别的新见解
J Med Chem. 2009 Dec 10;52(23):7640-52. doi: 10.1021/jm900718w.
6
Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.4-氨基-6-羟基-2-巯基嘧啶衍生物作为新型、强效和选择性A3腺苷受体拮抗剂
J Med Chem. 2008 Mar 27;51(6):1764-70. doi: 10.1021/jm701159t. Epub 2008 Feb 13.
7
New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.新型2-芳基吡唑并[4,3-c]喹啉衍生物作为强效和选择性人A3腺苷受体拮抗剂。
J Med Chem. 2005 Jul 28;48(15):5001-8. doi: 10.1021/jm050125k.
8
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.新型8-杂环黄嘌呤衍生物作为高效且选择性的人A2B腺苷受体拮抗剂的设计、合成及生物学评价
J Med Chem. 2004 Mar 11;47(6):1434-47. doi: 10.1021/jm0309654.
9
Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.新型5-杂芳基氨基甲酰基氨基吡唑并[4,3-e]1,2,4-三唑并[1,5-c]嘧啶系列作为人A3腺苷受体拮抗剂的合成与生物学研究。杂芳基取代基对结合亲和力的影响及分子模拟研究。
J Med Chem. 2006 Mar 9;49(5):1720-9. doi: 10.1021/jm051147+.
10
Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.采用分子简化方法探索人 A3 腺苷受体拮抗剂的结合模式:从三唑并喹喔啉到嘧啶骨架的关键研究
J Med Chem. 2007 Dec 27;50(26):6596-606. doi: 10.1021/jm070852a. Epub 2007 Nov 30.

引用本文的文献

1
Glioblastoma: Current Status, Emerging Targets, and Recent Advances.胶质母细胞瘤:现状、新兴靶点及最新进展。
J Med Chem. 2022 Jul 14;65(13):8596-8685. doi: 10.1021/acs.jmedchem.1c01946. Epub 2022 Jul 5.
2
Cancer biology and molecular genetics of A adenosine receptor.A 腺苷受体的癌症生物学和分子遗传学。
Oncogene. 2022 Jan;41(3):301-308. doi: 10.1038/s41388-021-02090-z. Epub 2021 Nov 8.
3
Potent and selective A adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties.带有氨基酯作为异双功能部分的强效且选择性的 A 型腺苷受体拮抗剂。
RSC Med Chem. 2020 Dec 14;12(2):254-262. doi: 10.1039/d0md00380h. eCollection 2021 Mar 4.
4
Crystal structure and Hirshfeld surface analysis of 3-(4-meth-oxy-phen-yl)-1-methyl-4-phenyl-1-pyrazolo-[3,4-]pyrimidine.3-(4-甲氧基苯基)-1-甲基-4-苯基-1-吡唑并-[3,4-]嘧啶的晶体结构与 Hirshfeld 表面分析
Acta Crystallogr E Crystallogr Commun. 2019 Apr 16;75(Pt 5):638-641. doi: 10.1107/S2056989019004894. eCollection 2019 May 1.
5
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration.乐伐替尼和凡德他尼对取自活检或细针穿刺的原发性间变性甲状腺癌细胞的抗肿瘤作用
Front Endocrinol (Lausanne). 2018 Dec 18;9:764. doi: 10.3389/fendo.2018.00764. eCollection 2018.
6
Studies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A adenosine receptor.手性4-乙酰氨基-6-烷氧基-2-烷硫基嘧啶作为人A腺苷受体拮抗剂的对映选择性研究。
Medchemcomm. 2017 Nov 9;9(1):81-86. doi: 10.1039/c7md00375g. eCollection 2018 Jan 1.
7
A Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.腺嘌呤受体作为炎症的调节剂:从药物化学到治疗。
Med Res Rev. 2018 Jul;38(4):1031-1072. doi: 10.1002/med.21456. Epub 2017 Jul 6.
8
Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.以色酮核为基础的 MAO-B/A2AAR 双重结合支架的化学信息组学分析。
Curr Neuropharmacol. 2017 Nov 14;15(8):1117-1135. doi: 10.2174/1570159X15666170116145316.
9
Crystal structure of 1,5-diethyl-3',5'-di-phenyl-1,5-di-hydro-3'H-spiro-[pyra-zolo[3,4-d]pyrimidine-4,2'-[1,3,4]thia-diazole].1,5 - 二乙基 - 3',5' - 二苯基 - 1,5 - 二氢 - 3'H - 螺[吡唑并[3,4 - d]嘧啶 - 4,2'-[1,3,4]噻二唑]的晶体结构
Acta Crystallogr E Crystallogr Commun. 2015 Sep 26;71(Pt 10):o769-70. doi: 10.1107/S2056989015017405. eCollection 2015 Oct 1.
10
CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.CLM29和CLM24这两种吡唑并嘧啶衍生物,在体外对间变性甲状腺癌具有抗肿瘤活性,无论是否存在BRAF突变。
Endocrine. 2016 Jul;53(1):136-44. doi: 10.1007/s12020-015-0717-4. Epub 2015 Aug 19.